Search

VOXZOGO®▼(vosoritide) is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed.

The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

See the data

Oscar, 9 years old, living with achondroplasia,

receiving VOXZOGO® as part of a clinical trial

 

 

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Play

Learn about Oscar’s treatment journey with VOXZOGO®

The parents’ story of a child living with achondroplasia.

See how VOXZOGO works

See how VOXZOGO® works

VOXZOGO® targets overactive fibroblast growth factor receptor 3 (FGFR3) signaling and acts as a positive regulator of endochondral bone growth.1

Get the facts

Find out more from BioMarin

Prescriber Resources

Access prescribing tools and information about VOXZOGO®

Dosing Calculator >

PBS Prescribing Codes >

Administration >

Achondroplasia Patient Caregiver Resources

Patient and caregiver resources

Useful information and support for your patients

Access here

References:

  1. VOXZOGO Product Information, 2022.